HighTower Advisors
BIO icon

HighTower Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

HighTower Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400
Closed -$35K – 3170
2022
Q2 		$35K Buy
+400
New +$208K ﹤0.01% 2950

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HighTower Advisors's BIO Position: Q1 2026 in Review

HighTower Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 40% in Q1 2026, selling an estimated $996K and leaving 5,124 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1940.

HighTower Advisors first reported a position in BIO in Q4 2015 and has held it in 38 quarters since. The position peaked at $5.38M in Q4 2021. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • HighTower Advisors held 5,124 shares of Bio-Rad Laboratories Class A worth $1.43M as of Q1 2026.
  • HighTower Advisors sold 3,460 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $996K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1940 holding.
  • HighTower Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and has held it in 38 quarters since.
  • HighTower Advisors's Bio-Rad Laboratories Class A position peaked at $5.38M in Q4 2021.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.